RECURRENT MANTLE CELL LYMPHOMA
Clinical trials for RECURRENT MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Combination therapy aims to outsmart tough lymphoma
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug nemtabrutinib to a CAR T-cell therapy called brexu-cel can help people with mantle cell lymphoma that has come back or not responded to treatment. Nemtabrutinib blocks a protein that helps cancer cells grow, while brexu-cel uses a …
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
New drug duo takes on tough lymphoma
Disease control Not yet recruitingThis early-stage trial tests a new drug, golcadomide, combined with rituximab for people with mantle cell lymphoma that has come back or stopped responding to treatment. The study aims to find the safest dose and see if the combination can shrink tumors. About 58 adults will take…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC